SRP1020

PreclinicalSmall molecule

SShanghai SciBrunch Therapeutics Co., Ltd.

SRP1020 is one of 76 small molecule programs targeting Solid Tumor. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorRecruiting

Patients With Advanced Solid TumorsRecruiting

Solid TumorPreclinical

Recruiting

Patients With Advanced Solid TumorsPreclinical

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

3 2

Fludara

Sanofi

Preclinical

2 3

DATROWAY

Daiichi Sankyo

Preclinical

1 4

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 5

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 6

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 7

Carboplatin AUC-5

Merck & Co.

Preclinical

1 8

Tulmimetostat

Novartis

Preclinical

1 9

IL-2

FFate Therapeutics

Preclinical

2 10

GT201

GGrit Biotechnology

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Solid Tumor

NCT07359066

Clinical

Trials by Indication[1]

Solid Tumor1 trial

An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors

Recruiting·SShanghai SciBrunch Therapeutics Co., Ltd.·Preclinical·NCT07359066·210 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SRP1020. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SRP1020 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SRP1020. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai SciBrunch Therapeutics Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShanghai SciBrunch Therapeutics Co., Ltd.

SRP1020

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News